Asuragen Inc., Austin, Tx., USA.
Exp Hematol. 2011 Oct;39(10):1030-1042.e7. doi: 10.1016/j.exphem.2011.07.008. Epub 2011 Jul 22.
The study investigated differential microRNA (miRNA) expression patterns in acute myeloid leukemia (AML) patients with intermediate-risk (IR) characteristics. After characterization and validation of miR-10a, which was specifically upregulated in nucleophosmin 1 (NPM1) mutant AML samples, functional consequences of miR-10a overexpression were further delineated in vitro.
Microarray analysis of miRNAs in bone marrow samples from AML (IR) patients with NPM1 mutations and healthy donors was performed to detect differential expression patterns. After validation of miRNA expression specific for NPM1 mutation in AML patients by quantitative reverse transcription polymerase chain reaction, a functional target gene search was conducted using complementary DNA microarray data from samples transfected with miR-10a. Potential target gene validation was done using transient transfection of K562 cells followed by Western blotting and luciferase reporter assay.
In comparison with wild-type samples, NPM1 mutant AML samples were shown to markedly overexpress miR-10a. Subsequent in vitro miR-10a overexpression induced differential gene expression as determined by microarray analysis. Here the murine double minute 4 (MDM4) gene turned out as a candidate gene for miR-10a. Validation of MDM4 in leukemic cells revealed a robust negative relationship between miR-10a overexpression and MDM4 downregulation. Furthermore, we determined an inverse association between miR-10a and MDM4 expression in AML (IR) samples with respect to their NPM1 mutational status.
miR-10a expression is highly characteristic for AML (IR) patients with NPM1 mutations and may influence its biological properties in AML by interfering with the p53 machinery partly regulated by MDM4.
研究具有中危(IR)特征的急性髓系白血病(AML)患者中差异微小 RNA(miRNA)表达模式。在核磷蛋白 1(NPM1)突变 AML 样本中特异性上调的 miR-10a 进行特征描述和验证后,进一步在体外阐明 miR-10a 过表达的功能后果。
对 NPM1 突变的 AML(IR)患者和健康供体的骨髓样本进行 miRNA 微阵列分析,以检测差异表达模式。通过定量逆转录聚合酶链反应验证 AML 患者 NPM1 突变特异性 miRNA 表达后,使用 miR-10a 转染样本的 cDNA 微阵列数据进行功能靶基因搜索。使用瞬时转染 K562 细胞进行潜在靶基因验证,随后进行 Western blot 和荧光素酶报告基因测定。
与野生型样本相比,NPM1 突变型 AML 样本明显过表达 miR-10a。随后通过微阵列分析,体外 miR-10a 过表达诱导了差异基因表达。在这里,双微体鼠基因 4(MDM4)基因被确定为 miR-10a 的候选基因。在白血病细胞中对 MDM4 的验证显示,miR-10a 过表达与 MDM4 下调之间存在明显的负相关关系。此外,我们确定了 AML(IR)样本中 miR-10a 和 MDM4 表达与 NPM1 突变状态之间的反比关系。
miR-10a 的表达在具有 NPM1 突变的 AML(IR)患者中具有高度特征性,并且通过干扰部分受 MDM4 调节的 p53 机制,可能影响其在 AML 中的生物学特性。